List view / Grid view
New research reveals how B cells balance mutation and clonal expansion to refine their antibodies. This discovery could lead to more targeted and effective vaccine designs for various diseases.
The nasal spray reduced influenza virus levels by >99.99 percent, which could safeguard public health if validated in humans.
The novel strategy demonstrates a strong immune response, both body-wide and specifically in the upper respiratory tract, in porcine models.
PVP-037, identified through a small molecule screen, induces a more durable and broader immune response to vaccines.
As antimicrobial resistance continues to advance, novel therapeutics are needed that stop infection and do not contribute to resistance. Australian biotech Recce Pharmaceuticals is paving the way for a new class of synthetic anti-infectives and providing hope for those with resistant infections. Recce’s lead candidate, RECCE® 327 (R327), is a…
The vaccine provided complete protection with no detectable virus in the lungs and could be a routine part of people’s medical treatment.
The study's findings could be applied to the development of new vaccine and therapeutic strategies for influenza.
A new vaccine, based on a nanoliposome that promotes proteins to be displayed on its surface, results in potent vaccine efficacy.
The interactions linking intestinal microbiota with the functionality of basally resident alveolar macrophages and severity of infection are revealed.
The new antibodies can neutralise certain H1 and H3 strains with or without the 133a insertion, which could lead to improved vaccines.
St. Jude Children’s Research Hospital, in collaboration with ESR Limited, discovered that specific immune cells present in individuals months before a flu infection can better predict symptom development compared to current antibody-based methods.
Researchers provide new insights into viral evolution and have significant implications for understanding and predicting the behaviour of influenza and other mutating diseases.
Australian researchers have tested a new nasal vaccine in mice, with the potential enhance protection against COVID-19.
H84T-BanLec has viral-blocking abilities by binding to polysaccharides that are present on the surface of the viruses.
Dr Christopher Locher, Versatope Therapeutics, explains why bacterial extracellular vesicles are ideally suited for recombinant vaccines because target antigens can be expressed as fusion proteins and targeted to the lumen, membrane or surface of the vesicles. These nano-size vesicles represent a potentially safe and simple subunit vaccine delivery platform that…
